MariTide: evidence, risks and legal status

What it is

Amgen's long-interval obesity candidate — an antibody-peptide conjugate notable for GIP receptor BLOCKADE (the opposite bet from tirzepatide's GIP activation). Currently in Phase 3.

How it works

Maritide (maridebart cafraglutide, formerly AMG 133) works differently from every other drug in this space, and the difference is the interesting part. It is an antibody-peptide conjugate: a monoclonal antibody that BLOCKS the GIP receptor, with GLP-1 agonist peptides chemically attached to it. So it agonises GLP-1 while antagonising GIP — the opposite of tirzepatide, which agonises both. That two drugs with opposite GIP actions both produce weight loss is one of the genuinely unresolved puzzles in metabolic pharmacology. The antibody backbone also gives it a very long half-life, which is what makes monthly or less-frequent administration plausible.

What human evidence shows

Phase 2 data reported large weight loss with infrequent dosing; the same program made news for GI tolerability challenges that its trial design continues to work through. Published evidence remains incomplete while Phase 3 runs.

The studies, one by one

INVESTIGATIONAL — not approved anywhere. Phase II results reported substantial weight reduction, and a phase III programme is underway.
Be careful with the slow-regain story: that observation comes from exploratory phase I work, not from the published phase II report, which evaluated outcomes through 52 weeks. Phase II part 2 was designed to examine maintenance, reduced-frequency dosing and discontinuation, and durability after stopping has not been publicly established in the primary publication.
Gastrointestinal adverse effects were common and were dose-limiting, consistent with the class.
Its GIP antagonism versus tirzepatide's GIP agonism remains unexplained — both approaches produce weight loss, and the field does not have a settled account of why.
Everything about long-term safety is unknown, as it is for any investigational agent.

Half-life and how long it lasts

An antibody-peptide conjugate with a very long half-life, which is why infrequent administration is possible and why effects persist well after stopping. It is given by injection. There is no approved product; anything sold as it outside a clinical trial is not what it claims to be.

Risks

Trial-reported GI tolerability problems, and an antibody-conjugate's long half-life means a bad reaction persists for weeks, not days. Complex biologics of this class are beyond the manufacturing reach of unregulated labs — any purported product outside a registered study cannot be assumed to be the investigational drug.

Who should never touch it

Everyone outside a clinical trial — it is investigational and unavailable through any lawful route
Anyone buying something sold under this name online, which cannot be what it claims

Interactions worth knowing

No characterised interaction profile outside the trial setting.
As a class, GLP-1 agonism slows gastric emptying, which can alter absorption of other oral medicines and raises aspiration risk around anaesthesia.

Stacking interactions

Documented interactions with other things people research. A compound not listed here does not mean the combination is safe — only that no specific interaction is on file.

AvoidSemaglutide